Processa Pharmaceuticals, Inc. Accrued Liabilities, Current
Processa Pharmaceuticals, Inc. (PCSA) had Accrued Liabilities, Current of $727.47 thousand as of 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current › Accounts Payable and Accrued Liabilities, Current
us-gaap:AccruedLiabilitiesCurrent · last filed 2026-08-14
- 2026-06-30: Accrued Liabilities, Current $727.47K.
- 2026-03-31: Accrued Liabilities, Current $1.14M.
- 2025-12-31: Accrued Liabilities, Current $1.18M.
- 2025-09-30: Accrued Liabilities, Current $1.02M.
| Period end | Accrued Liabilities, Current | Accrued Liabilities, Current as first filed |
|---|---|---|
| 2026-06-30 | $727.47K 10-Q · filed 2026-08-14 | |
| 2026-03-31 | $1.14M 10-Q · filed 2026-05-07 | |
| 2025-12-31 | $1.18M 10-Q · filed 2026-08-14 | |
| 2025-09-30 | $1.02M 10-Q · filed 2025-11-06 | |
| 2025-06-30 | $1.26M 10-Q · filed 2025-08-07 | |
| 2025-03-31 | $680.75K 10-Q · filed 2025-05-08 | |
| 2024-12-31 | $578.73K 10-K · filed 2026-03-18 | |
| 2024-09-30 | $412.81K 10-Q · filed 2024-10-30 | |
| 2024-06-30 | $505.40K 10-Q · filed 2024-08-13 | |
| 2024-03-31 | $465.62K 10-Q · filed 2024-05-10 | |
| 2023-12-31 | $146.27K 10-K · filed 2025-03-20 | |
| 2023-09-30 | $202.24K 10-Q · filed 2023-11-13 | |
| 2023-06-30 | $311.50K 10-Q · filed 2023-08-10 | |
| 2023-03-31 | $1.57M 10-Q · filed 2023-05-15 | |
| 2022-12-31 | $403.06K 10-K · filed 2024-03-29 | |
| 2022-09-30 | $216.41K 10-Q · filed 2022-11-08 | |
| 2022-06-30 | $307.41K 10-Q · filed 2022-08-11 | |
| 2022-03-31 | $292.57K 10-Q · filed 2022-05-12 | |
| 2021-12-31 | $279.26K 10-K · filed 2023-03-30 | |
| 2021-09-30 | $378.66K 10-Q · filed 2021-11-12 | |
| 2021-06-30 | $369.11K 10-Q · filed 2021-08-12 | |
| 2021-03-31 | $233.90K 10-Q · filed 2021-05-13 | |
| 2020-12-31 | $224.68K 10-K · filed 2022-03-30 | |
| 2020-09-30 | $397.60K 10-Q · filed 2020-11-12 | |
| 2020-06-30 | $317.25K 10-Q · filed 2020-08-05 | |
| 2020-03-31 | $233.50K 10-Q · filed 2020-05-15 | |
| 2019-12-31 | $213.24K 10-K · filed 2021-03-25 | |
| 2019-09-30 | $123.67K 10-Q · filed 2019-11-14 | |
| 2019-06-30 | $302.27K 10-Q · filed 2019-08-14 | |
| 2019-03-31 | $128.22K 10-Q · filed 2019-05-14 | |
| 2018-12-31 | $103.26K 10-K · filed 2020-03-06 | |
| 2018-09-30 | $367.55K 10-Q · filed 2018-11-14 | |
| 2018-06-30 | $161.91K 10-Q · filed 2018-08-14 | |
| 2018-03-31 | $170.31K 10-Q · filed 2018-05-21 | |
| 2017-12-31 | $64.43K 10-K/A · filed 2019-04-08 | |
| 2017-09-30 | $19.75K 10-Q · filed 2017-11-20 | |
| 2017-06-30 | $147.62K 10-Q · filed 2017-10-04 | |
| 2017-03-31 | $144.03K 10-Q · filed 2017-10-04 | |
| 2016-12-31 | $83.00K 10-K · filed 2018-04-16 | $134.51K 10-K · filed 2017-09-25 |
| 2016-09-30 | $123.69K 10-Q · filed 2017-09-08 | |
| 2016-06-30 | $112.86K 10-Q · filed 2017-08-30 | |
| 2016-03-31 | $93.86K 10-Q · filed 2017-08-07 | |
| 2015-12-31 | $95.34K 10-K · filed 2017-09-25 | |
| 2015-09-30 | $101.14K 10-Q · filed 2015-12-01 | |
| 2015-06-30 | $72.46K 10-Q · filed 2015-08-19 | |
| 2015-03-31 | $80.84K 10-Q · filed 2015-05-15 | |
| 2014-12-31 | $94.17K 10-K · filed 2017-06-19 | $105.61K 10-K · filed 2015-04-14 |
| 2014-09-30 | $130.16K 10-Q · filed 2014-11-13 | |
| 2014-06-30 | $155.47K 10-Q · filed 2014-08-19 | |
| 2014-03-31 | $160.24K 10-Q · filed 2014-05-14 | |
| 2013-12-31 | $256.09K 10-K · filed 2015-04-14 | |
| 2013-09-30 | $165.38K 10-Q · filed 2013-11-08 | |
| 2013-06-30 | $111.28K 10-Q/A · filed 2013-09-06 | |
| 2012-12-31 | $112.48K 10-K · filed 2014-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |